

REDEFINING SURVIVAL EXPECTATIONS IN LUNG CANCER

Fira de Barcelona Gran Via • Hall 6, Barcelona (2005)
Barcelona, Spain

Tuesday, 10 September 2019

13:00 - 14:30

Chair: Johan Vansteenkiste (Belgium)

AGENDA

12:00 - 12:05	Welcome and Introduction <i>Johan Vansteenkiste</i>
12:05 - 12:20	Scientific Rationale for Combining Immune Check Point Inhibitors and Chemotherapy <i>Johan Vansteenkiste</i>
12:20 - 12:50	Role of IO in mNSCLC Pro - Use of IO/Chemotherapy Combinations or Monotherapy in 1L Con - Preserve Option of IO Use for 2nd Line <i>Stephen Liu - Pro</i> <i>Ben Levy - Con</i>
12:50 - 13:05	Patient Cases <i>Ben Levy</i>
13:05 - 13:20	Beyond NSCLC - SCLC, Mesothelioma <i>Stephen Liu</i>
13:20 - 13:30	Q&A
13:30	Closing Remarks <i>Johan Vansteenkiste</i>

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

CHAIR

Johan Vansteenkiste

Professor and Head of Clinic
Respiratory Oncology Unit
University Hospital KU Leuven
Leuven, Belgium

FACULTY

Benjamin Levy

Clinical Director of Medical
Oncology
Johns Hopkins Sidney Kimmel
Cancer Center
Washington, DC, USA
Associate Professor of Oncology
Johns Hopkins University
School of Medicine
Baltimore, MD, USA

Stephen Liu

Department of Medicine
Hematology/Oncology
Georgetown University Medical
Center
Washington, DC, USA

